🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

444 results for “Ology” Clear

  1. neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2+ Metastatic Breast Cancer (MBC)

    phase 3 small molecule completed

    1 trial

  2. sotrovimab

    Vir Biotechnology

    Covid19

    phase 3 mab terminated

    3 trials

  3. 177Lu PSMA I&T solution for injection

    Ology Bioservices Ireland LTD

    Recurrent grade 3 and grade 4 glioma

    phase 2 small molecule active

    1 trial

  4. A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

    Ology Bioservices Ireland LTD

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)"

    phase 2 other active

    1 trial

  5. A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

    Amgen Technology (Ireland) UC

    Ulcerative Colitis (UC)

    phase 2 other active

    1 trial

  6. A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

    Amgen Technology (Ireland) UC

    Ulcerative Colitis (UC)

    phase 2 other active

    1 trial

  7. A phase II trial aiming to investigate the safety and clinical activity of belantamab mafodotin in adult patients with primary immune thrombocytopenia previously treated with a thrombopoietin receptor agonist and/or rituximab after corticosteroid first-line therapy - BONSAI

    Ology Bioservices Ireland LTD

    Primary Immune Thrombocytopenia

    phase 2 other active

    1 trial

  8. AG10

    BridgeBio Oncology Therapeutics

    Familial ATTR-CM (ATTRm-CM, or FAC)

    phase 2 small molecule completed

    1 trial

  9. AG10

    BridgeBio Oncology Therapeutics

    Amyloid Cardiomyopathy

    phase 2 small molecule active

    1 trial

  10. AMG 133, Placebo for AMG 133

    Amgen Technology (Ireland) UC

    Overweight and Obesity

    phase 2 small molecule active

    1 trial

  11. AMG 193

    Amgen Technology (Ireland) UC

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. AMG 193, AMG 193, AMG 193

    Amgen Technology (Ireland) UC

    Advanced MTAP-null solid tumors

    phase 2 small molecule active

    1 trial

  13. AMG 193, IDE397, AMG 193, IDE397, AMG 193

    Amgen Technology (Ireland) UC

    In Part 1, subjects with advanced MTAP-null solid tumors and, in Part 2, subjects with advanced MTAP-null Non Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  14. AMG 732

    Amgen Technology (Ireland) UC

    Thyroid Eye Disease

    phase 2 small molecule active

    1 trial

  15. APX005M

    Pyxis Oncology

    Melanoma

    phase 2 small molecule terminated

    1 trial

  16. AZACITIDINE

    ALX ONCOLOGY HOLDINGS INC

    Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease

    phase 2 small molecule active

    1 trial

  17. AZD5363

    Cardiff Oncology

    Estrogen Receptor Positive Breast Cancer

    phase 2 small molecule active

    1 trial

  18. AZITROMICINA ZENTIVA 500 mg compresse rivestite con film, Bassado 100 mg compresse, CEBION

    Sana Biotechnology

    Breast Cancer

    phase 2 small molecule active

    1 trial

  19. Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset

    Adaptive Biotechnologies Corp

    Chronic Tonal Tinnitus

    phase 2 other completed

    1 trial

  20. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Small Cell Lung Cancer ( SCLC )

    phase 2 small molecule active

    1 trial

  22. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Hormone Receptor Positive HER-2 Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  23. An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies

    Pharma Mar S.A.

    Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thrombotic microangiopathy

    phase 2 other active

    1 trial

  24. Aspirin

    Cardiff Oncology

    Venous Leg Ulcer

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources